• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Progenity, Inc. (Amendment)

    8/27/21 4:22:59 PM ET
    $PROG
    Specialty Chemicals
    Consumer Durables
    Get the next $PROG alert in real time by email
    SC 13D/A 1 d214429dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Progenity, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    74319F107

    (CUSIP Number)

    Andrew C. Hyman, Esq.

    Athyrium Capital Management, LP

    505 Fifth Avenue, 18th Floor

    New York, New York 10017

    (212) 402-6925

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 24, 2021

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-l(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      Name of reporting person

     

      Athyrium Opportunities Fund (A) LP

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      4,211,977

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      4,211,977

    11    

      Aggregate amount beneficially owned by each reporting person

     

      4,211,977

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      2.7%

    14  

      Type of reporting person

     

      PN


      1    

      Name of reporting person

     

      Athyrium Opportunities Fund (B) LP

      2  

      Check the appropriate box if a member of a group*

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      2,329,083

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      2,329,083

    11    

      Aggregate amount beneficially owned by each reporting person

     

      2,329,083

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      1.5%

    14  

      Type of reporting person

     

      PN


      1    

      Name of reporting person

     

      Athyrium Opportunities III Co-Invest 1 LP

      2  

      Check the appropriate box if a member of a group*

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      27,361,457

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      27,361,457

    11    

      Aggregate amount beneficially owned by each reporting person

     

      27,361,457

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      17.5%

    14  

      Type of reporting person

     

      PN


      1    

      Name of reporting person

     

      Athyrium Opportunities III Acquisition LP

      2  

      Check the appropriate box if a member of a group*

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      7,256,543

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      7,256,543

    11    

      Aggregate amount beneficially owned by each reporting person

     

      7,256,543

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      4.6%

    14  

      Type of reporting person

     

      PN


      1    

      Name of reporting person

     

      Athyrium Opportunities III Acquisition 2 LP

      2  

      Check the appropriate box if a member of a group*

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      27,925,812

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      27,925,812

    11    

      Aggregate amount beneficially owned by each reporting person

     

      27,925,812

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      17.8%

    14  

      Type of reporting person

     

      PN


      1    

      Name of reporting person

     

      Athyrium Opportunities 2020 LP

      2  

      Check the appropriate box if a member of a group*

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      4,583,333

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      4,583,333

    11    

      Aggregate amount beneficially owned by each reporting person

     

      4,583,333

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      2.9%

    14  

      Type of reporting person

     

      PN


      1    

      Name of reporting person

     

      Athyrium Opportunities Associates LP

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      6,541,060

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      6,541,060

    11    

      Aggregate amount beneficially owned by each reporting person

     

      6,541,060

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      4.2%

    14  

      Type of reporting person

     

      PN


      1    

      Name of reporting person

     

      Athyrium Opportunities Associates GP LLC

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      6,541,060

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      6,541,060

    11    

      Aggregate amount beneficially owned by each reporting person

     

      6,541,060

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      4.2%

    14  

      Type of reporting person

     

      OO


      1    

      Name of reporting person

     

      Athyrium Capital Management, LP

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      6,541,060

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      6,541,060

    11    

      Aggregate amount beneficially owned by each reporting person

     

      6,541,060

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      4.2%

    14  

      Type of reporting person

     

      PN / IA


      1    

      Name of reporting person

     

      Athyrium Capital Holdings, LLC

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      6,541,060

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      6,541,060

    11    

      Aggregate amount beneficially owned by each reporting person

     

      6,541,060

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      4.2%

    14  

      Type of reporting person

     

      OO


      1    

      Name of reporting person

     

      Jeffrey A. Ferrell

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      United States

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      73,668,205

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      73,668,205

    11    

      Aggregate amount beneficially owned by each reporting person

     

      73,668,205

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      47.0%

    14  

      Type of reporting person

     

      IN


      1    

      Name of reporting person

     

      Athyrium Opportunities Advisers LLC

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      6,541,060

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      6,541,060

    11    

      Aggregate amount beneficially owned by each reporting person

     

      6,541,060

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      4.2%

    14  

      Type of reporting person

     

      OO / IA


      1    

      Name of reporting person

     

      NB Alternatives Advisers LLC

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☒

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      6,541,060

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      6,541,060

    11    

      Aggregate amount beneficially owned by each reporting person

     

      6,541,060

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      4.2%

    14  

      Type of reporting person

     

      OO / IA


      1    

      Name of reporting person

     

      NB Alternatives GP Holdings LLC

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      6,541,060

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      6,541,060

    11    

      Aggregate amount beneficially owned by each reporting person

     

      6,541,060

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      4.2%

    14  

      Type of reporting person

     

      OO


      1    

      Name of reporting person

     

      NB Alternatives Holdings LLC

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      6,541,060

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      6,541,060

    11    

      Aggregate amount beneficially owned by each reporting person

     

      6,541,060

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      4.2%

    14  

      Type of reporting person

     

      OO


      1    

      Name of reporting person

     

      Athyrium Opportunities Associates Co-Invest LLC

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      27,361,457

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      27,361,457

    11    

      Aggregate amount beneficially owned by each reporting person

     

      27,361,457

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      17.5%

    14  

      Type of reporting person

     

      OO


      1    

      Name of reporting person

     

      Athyrium Funds GP Holdings LLC

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      67,127,145

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      67,127,145

    11    

      Aggregate amount beneficially owned by each reporting person

     

      67,127,145

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      42.8%

    14  

      Type of reporting person

     

      OO


      1    

      Name of reporting person

     

      Athyrium Opportunities Associates III LP

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      39,765,688

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      39,765,688

    11    

      Aggregate amount beneficially owned by each reporting person

     

      39,765,688

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      25.4%

    14  

      Type of reporting person

     

      PN


      1    

      Name of reporting person

     

      Athyrium Opportunities Associates III GP LLC

      2  

      Check the appropriate box if a member of a group

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only

     

      4  

      Source of funds

     

      OO

      5  

      Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

     

         7     

      Sole voting power

     

      0

         8   

      Shared voting power

     

      39,765,688

         9   

      Sole dispositive power

     

      0

       10   

      Shared dispositive power

     

      39,765,688

    11    

      Aggregate amount beneficially owned by each reporting person

     

      39,765,688

    12  

      Check box if the aggregate amount in Row (11) excludes certain shares

     

      ☐

    13  

      Percent of class represented by amount in Row (11)

     

      25.4%

    14  

      Type of reporting person

     

      OO


    Explanatory Note

    This Amendment No. 3 (this “Amendment No. 3”) amends and supplements the Schedule 13D originally filed by the Reporting Persons (as defined below) with the Securities and Exchange Commission (the “SEC”) on July 6, 2020, as amended by Amendment No. 1 thereto filed with the SEC on December 7, 2020, and as amended by Amendment No. 2 thereto filed with the SEC on June 21, 2021 (as amended to date, this “Schedule 13D”).

     

    Item 1.

    Security and Issuer.

    This Schedule 13D relates to the common stock, par value $0.001 per share (“Common Stock”), of Progenity, Inc., a Delaware corporation (the “Company”). The address of the principal executive offices of the Company is 4330 La Jolla Village Drive, Suite 200, San Diego, California 92122.

     

    Item 2.

    Identity and Background.

    (a)-(c) & (f) This Schedule 13D is filed jointly by the following persons pursuant to Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934:

    (1) Athyrium Opportunities Fund (A) LP, a Delaware limited partnership (“Fund A”), is an investment partnership engaged in the business of making equity and debt investments;

    (2) Athyrium Opportunities Fund (B) LP, a Delaware limited partnership (“Fund B” and, together with Fund A, the “Joint Funds”), is an investment partnership engaged in the business of making equity and debt investments;

    (3) Athyrium Opportunities III Co-Invest 1 LP, a Delaware limited partnership (“Co-Invest LP”), is an investment partnership engaged in the business of making equity and debt investments;

    (4) Athyrium Opportunities III Acquisition LP, a Delaware limited partnership (“Acquisition LP”), is an investment partnership engaged in the business of making equity and debt investments;

    (5) Athyrium Opportunities III Acquisition 2 LP, a Delaware limited partnership (“Acquisition 2 LP” and, together with Acquisition LP, the “AOIII Acquisition Funds”), is an investment partnership engaged in the business of making equity and debt investments;

    (6) Athyrium Opportunities 2020 LP, a Delaware limited partnership (“2020 LP” and, together with the Joint Funds, Co-Invest LP and the AOIII Acquisition Funds, the “Funds”), is an investment partnership engaged in the business of making equity and debt investments;

    (7) Athyrium Opportunities Associates LP, a Delaware limited partnership (“Associates LP”), is engaged in the business of being the general partner of the Joint Funds;

    (8) Athyrium Opportunities Associates GP LLC, a Delaware limited liability company (“Associates GP”), is engaged in the business of being the general partner of Associates LP;

    (9) Athyrium Capital Management, LP, a Delaware limited partnership (“ACM”), is engaged in the business of being a member of Associates GP and an investment sub-adviser to Opportunities Advisers (as defined below);

    (10) Athyrium Capital Holdings, LLC, a Delaware limited liability company (“ACH”), is engaged in the business of being the general partner of ACM;


    (11) Jeffrey A. Ferrell is an individual citizen of the United States whose principal occupation is to serve as the Managing Member of ACH and GP Holdings (as defined below) and the President of ACM, Associates GP, Associates III GP (as defined below) and Associates Co-Invest (as defined below);

    (12) Athyrium Opportunities Advisers LLC, a Delaware limited liability company (“Opportunities Advisers”), is engaged in the business of being an investment adviser to the Joint Funds;

    (13) NB Alternatives Advisers LLC, a Delaware limited liability company (“Alternatives Advisers”), is engaged in the business of being the sole member of Opportunities Advisers;

    (14) NB Alternatives GP Holdings LLC, a Delaware limited liability company (“Alternatives GP”), is engaged in the business of being a member of Associates GP;

    (15) NB Alternatives Holdings LLC, a Delaware limited liability company (“Alternatives Holdings”), is engaged in the business of being the sole member of Alternatives GP and a member of Alternatives Advisers;

    (16) Athyrium Opportunities Associates Co-Invest LLC, a Delaware limited liability company (“Associates Co-Invest”), is engaged in the business of being the general partner of Co-Invest LP;

    (17) Athyrium Funds GP Holdings LLC, a Delaware limited liability company (“GP Holdings”), is engaged in the business of being the managing member of Associates Co-Invest and Associates III GP (as defined below);

    (18) Athyrium Opportunities Associates III LP, a Delaware limited partnership (“Associates III LP”), is engaged in the business of being the general partner of the AOIII Acquisition Funds and 2020 LP; and

    (19) Athyrium Opportunities Associates III GP LLC, a Delaware limited liability company (“Associates III GP”), is engaged in the business of being the general partner of Associates III LP.

    The persons described in (1) through (19) above are referred to herein as the “Reporting Persons.” A list of the directors, executive officers, managers, members and partners, as applicable, of each Reporting Person (collectively, the “Covered Persons”) is attached hereto as Annex A and is incorporated by reference herein. To the knowledge of the Reporting Persons, each of the Covered Persons that is a natural person is a United States citizen, except for Elin Strong, who is a citizen of Norway.

    The principal business address of each of the Reporting Persons listed as (1)-(2), (7)-(8), (12) and (15), and each Covered Person associated with the foregoing Reporting Persons, is c/o NB Alternatives Advisers LLC, 1290 Avenue of the Americas, New York, New York 10104.

    The principal business address of each of the Reporting Persons listed as (3)-(6), (9)-(11) and (16)-(19) and each associated Covered Person is c/o Athyrium Capital Management, LP, 505 Fifth Avenue, Floor 18, New York, New York 10017.

    The principal business address of each of the Reporting Persons listed as (13)-(14), and each Covered Person associated with the foregoing Reporting Persons, is c/o NB Alternatives Advisers LLC, 325 N. Saint Paul Street, Suite 4900, Dallas, TX 75201.

    (d) During the last five years, none of the Reporting Persons or, to their knowledge, none of the Covered Persons, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).


    (e) On December 17, 2018, the SEC announced that Alternatives Advisers, without admitting or denying any wrongdoing, consented to the entry of an order (the “Order”) by the SEC focused solely on certain expense allocations relating to the Business Services Platform (the “BSP”), a team within the Dyal Capital Partners (“Dyal”) division focused on providing client development, talent management, operational advisory and other services to the partner managers in which the Dyal funds invest. Following the completion of the Blue Owl transaction (as described below), no businesses of Alternatives Advisers utilize the BSP and allocates the expense associated with the BSP to an Alternatives Advisers-advised fund. The SEC Order had no finding of intentional wrongdoing or fraud, and found that the issues relating to the BSP expenses ceased in 2017. According to the SEC Order, with respect to certain of the Dyal funds, the Dyal funds’ manager did not appropriately allocate a portion of the BSP expenses to certain Dyal funds and did not have proper policies and procedures in place to ensure that all allocations were related to the utilization of the BSP. The SEC Order required Alternatives Advisers to cease and desist from committing or causing any violations and future violations of Sections 206(2) and 206(4) of the Advisers Act, as amended, and Rules 206(4)-7 and 206(4)-8 thereunder. Alternatives Advisers agreed as part of the settlement to pay disgorgement of $2,073,988 (plus prejudgment interest of $284,620) to certain Dyal funds covering 2012-2016, and pay a civil monetary penalty of $375,000 to the SEC. The civil monetary penalty was satisfied on January 3, 2019. The disgorgement and prejudgment interest was satisfied on June 7, 2019. On May 19, 2021, the strategic combination between Dyal and Owl Rock Capital Group became effective, and Dyal is now part of Blue Owl Capital Inc. (“Blue Owl”), a company that trades on the NYSE as “OWL.”

    Other than as disclosed in the foregoing paragraph, during the last five years, none of the Reporting Persons or, to their knowledge, none of the Covered Persons, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

    On October 27, 2017, the Company and Co-Invest LP entered into a Series B Preferred Stock Purchase Agreement (the “2017 Series B Stock Purchase Agreement”), which provided for the sale of shares of Series B Preferred Stock at a purchase price of $3.53 per share for an aggregate purchase price of $50.0 million. Also on October 27, 2017, the Company issued the Warrant (as defined below) to Co-Invest LP providing the right to purchase additional shares of Series B Preferred Stock.

    On August 27, 2019, the Company and Acquisition LP entered into a Series B Preferred Stock Purchase Agreement pursuant to which Acquisition LP purchased shares of Series B Preferred Stock at $2.75 per share for an aggregate purchase price of $25.0 million. Also on August 27, 2019, the Company exchanged shares of its Series B Preferred Stock for the shares of its Series A-1 Preferred Stock held by the Joint Funds, which were acquired on June 12, 2013 for an aggregate purchase price of $11.2 million.

    On November 12, 2019, the Company and Acquisition LP entered into a Series B Stock Preferred Stock Purchase Agreement (the “2019 Series B Stock Purchase Agreement”) pursuant to which Acquisition LP purchased additional shares of Series B Preferred Stock at $2.25 per share for an aggregate purchase price of $25.0 million. The conversion price of the Series B Preferred Stock and exercise price of the Warrant were lowered from $2.75 to $2.25 per share (or $13.90 per share as a result of the reverse stock split effected on June 10, 2020). Also on November 12, 2019, Acquisition 2 LP acquired all of the securities of the Company held by Acquisition LP.

    On December 19, 2019 and February 28, 2020, Acquisition 2 LP purchased additional shares of Series B Preferred Stock pursuant to the 2019 Series B Stock Purchase Agreement for an aggregate purchase price of $25.0 million and $10.0 million, respectively, at a purchase price of $2.25 per share.


    On March 31, 2020, Co-Invest LP and the Company entered into the First Amendment to the Credit Agreement (the “Credit Agreement Amendment”) providing for the payment in shares of the Company’s Series B Preferred Stock of the interest on the amount outstanding under the applicable credit agreement.

    On April 3, 2020, the Company and Acquisition 2 LP entered into a Series B Preferred Stock Purchase Agreement pursuant to which Acquisition 2 LP purchased additional shares of Series B Preferred Stock at $2.25 per share for an aggregate purchase price of $10.0 million.

    On May 8, 2020, the Company and 2020 LP entered into a Note Purchase Agreement pursuant to which 2020 LP purchased an unsecured convertible promissory note (the “Convertible Promissory Note”) with an annual interest rate of 8.0% and in an aggregate principal amount of $15.0 million.

    In connection with the consummation of the Company’s initial public offering of its Common Stock, the Series B Preferred Stock and the Convertible Promissory Note converted, automatically and without any additional consideration, into 18,319,853 and 1,250,000 shares, respectively, of Common Stock. Further, on June 23, 2020, in connection with the initial public offering of the Company’s Common Stock, 2020 LP purchased 3,333,333 shares of Common Stock at a price of $15.00 per share. The funds used to purchase such shares were composed of the investment capital of 2020 LP.

    On December 7, 2020, the Company consummated a follow-on public offering of its Common Stock and a concurrent private placement of its 7.25% convertible senior notes due 2025 (the “7.25% Convertible Notes”). Acquisition 2 purchased 4,128,440 shares of Common Stock, and Acquisition LP purchased an aggregate principal amount of $25,000,000 of the 7.25% Convertible Notes in connection with the offerings. Such shares of Common Stock were purchased for $3.27 per share of Common Stock for an aggregate purchase price of $13.5 million, and such 7.25% Convertible Notes were purchased for $25.0 million in cash, in each case at the same price offered to the public. The funds used to purchase such shares and 7.25% Convertible Notes, as applicable, were composed of the investment capital of the applicable Fund. At the same time, Co-Invest LP consummated an agreement to receive an aggregate principal amount of $78,500,000 of the 7.25% Convertible Notes and $95,833.33 in cash in exchange for the cancellation of the $78.6 million in principal and accrued and unpaid interest outstanding, as well as a prepayment penalty, under the Company’s credit agreement for which Co-Invest LP acted as the lender and collateral agent.

    On June 1, 2021, Acquisition LP and Co-Invest LP entered into a Consent and Waiver Agreement and, on May 27, 2021, a Stock Issuance Agreement (the “Stock Issuance Agreement”), each with the Company, pursuant to which Acquisition LP and Co-Invest LP agreed to forgo and waive their right to receive interest in cash due on the 7.25% Convertible Notes held by Acquisition LP and Co-Invest LP, in exchange for the issuance of shares of Common Stock equal to $3,626,812.50, the amount of cash interest so waived, for a price of $2.86 per share. Pursuant to the Stock Issuance Agreement, Acquisition LP acquired 306,308 shares of Common Stock and Co-Invest LP acquired 961,807 shares of Common Stock.

    On June 14, 2021, the Company consummated a private placement of units (the “Private Placement”), with each unit consisting of one share of Common Stock and the right to buy an additional share of Common Stock for the exercise price specified in the warrant conferring such right (the “Common Stock Warrant”). In connection with the Private Placement, Acquisition 2 LP purchased 8,097,166 units for a price of $2.47 per unit and with an aggregate purchase price of $20.0 million.


    Item 4.

    Purpose of Transaction.

    The Reporting Persons acquired the securities reported herein for investment purposes and intend to review their investments in the Company on a continuing basis. Depending on various factors, including but not limited to the Company’s financial position and strategic direction, price levels of the Common Stock, conditions in the securities markets, various laws and regulations applicable to the Company and companies in its industry and the Reporting Persons’ ownership in the Company, and general economic and industry conditions, the Reporting Persons may in the future take actions with respect to their investment in the Company as they deem appropriate, including changing their current intentions, with respect to any or all matters required to be disclosed herein. Without limiting the foregoing, and subject to any applicable limitations described in Item 6 below, the Reporting Persons may, from time to time, acquire or cause affiliates to acquire additional shares of Common Stock or other securities of the Company (including any combination or derivative thereof), dispose, or cause affiliates to dispose, of some or all of their Common Stock or other securities of the Company or continue to hold, or cause affiliates to hold, Common Stock or other securities of the Company.

    In addition, the Reporting Persons have had and intend to continue having discussions, from time to time, with management and the board of directors of the Company, and may engage with other stockholders or securityholders of the Company and other relevant parties, or take other actions concerning, the Company’s business, lines of business, operations, strategy, previously announced restructuring, plans and prospects; any extraordinary corporate transactions (including, but not limited to, a merger, reorganization or liquidation); sales of a material amount of assets or divestitures; a change in the board of directors or management; a material change in the capitalization or dividend policies; other material changes in the Company’s business, lines of business, or corporate structure; or similar actions.

    Except as set forth herein, or as would occur upon completion of any of the matters discussed herein, the Reporting Persons have no present plans, proposals or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Although the foregoing reflects activities presently contemplated by the Reporting Persons and each other individuals named in Item 2 with respect to the Company, the foregoing is subject to change at any time.

    The information set forth under Items 3 and 6 is incorporated by reference herein.

     

    Item 5.

    Interest in Securities of the Issuer.

    (a)-(b) The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.

    The Reporting Persons beneficially own in the aggregate 73,668,205 shares of Common Stock, which represents approximately 47.0% of the outstanding shares of Common Stock. All calculations of percentage ownership in this Schedule 13D are based on (i) 79,406,317 shares of Common Stock outstanding as reported in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021, (ii) plus 40,000,000 shares of Common Stock issued by the Company on August 24, 2021 in a registered public offering, and (iii) plus the shares issuable upon conversion of the 7.25% Convertible Notes held by the Reporting Persons and upon exercise of the Warrant and the Common Stock Warrant by the Reporting Persons.

    To the knowledge of the Reporting Persons, none of the Covered Persons directly owns any shares of Common Stock; provided, however, that because of each Covered Persons’ status as a director, executive officer, manager, member or partner of a Reporting Person, a Covered Person may be deemed to be the beneficial owner of the shares of Common Stock beneficially owned by such Reporting Person. Except to the extent of their pecuniary interest, each of the Covered Persons disclaims beneficial ownership of the shares of the Common Stock reported herein and the filing of this Schedule 13D shall not be construed as an admission that any such Covered Person is the beneficial owner of any securities covered by this statement.

    In accordance with the SEC Release No. 34-39538 (January 12, 1998) (the “Release”), this Schedule 13D reflects the securities beneficially owned by certain operating units (collectively, the “NB Alts Reporting Units”) of Neuberger Berman Group LLC and its subsidiaries and affiliates (collectively, “NBG”). This Schedule 13D does not reflect securities, if any, beneficially owned by any operating units of NBG whose ownership of securities is disaggregated from that of the NB Alts Reporting Units in accordance with the Release.

    (c) Except as described in Item 3 of this Schedule 13D, none of the Reporting Persons or, to their knowledge, none of the Covered Persons, has had any transactions in the Common Stock during the past 60 days.


    (d) Except as set forth herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Common Stock.

    (e) Not applicable.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Fourth Amended and Restated Investors’ Rights Agreement

    On August 27, 2019, the Joint Funds, Co-Invest LP and Acquisition LP (the “Athyrium Parties”) entered into a fourth amended and restated investors’ rights agreement (the “Investors’ Rights Agreement”) with the Company and the other stockholders of the Company. The Investors’ Rights Agreement provides that the stockholders of the Company have certain registration rights described below. On November 12, 2019, in connection with its acquisition of the securities of the Company previously held by Acquisition LP, Acquisition 2 LP signed a joinder agreement to the Investors’ Rights Agreement and became one of the Athyrium Parties discussed below.

    The registration rights described below will expire (i) five years after the completion of the Company’s initial public offering, (ii) with respect to any Athyrium Party, at the time such Athyrium Party can sell all of its registrable securities under Rule 144 or another similar exemption under the Securities Act of 1933, as amended (the “Securities Act”), without limitation during a three-month period without registration or (iii) upon termination of the Investors’ Rights Agreement.

    The key registration rights under the Investors’ Rights Agreement are as follows:

     

      •  

    Demand Registration Rights. At any time beginning 210 days after the effective date of the registration statement for the Company’s initial public offering, the holders of 50% or more of the registrable securities then outstanding may make a written request that the Company register all or a portion of their shares, subject to certain specified exceptions and conditions. The Company will then prepare and file a registration statement as requested, unless, in the good faith judgment of the Company’s board of directors, such registration would be seriously detrimental to the Company and its stockholders and filing should be deferred.

     

      •  

    Piggyback Registration Rights. Subject to certain specified exceptions, if the Company proposes to register any of its securities under the Securities Act either for its own account or for the account of other stockholders, the holders of shares having registration rights are entitled to written notice and certain “piggyback” registration rights allowing them to include their shares in the Company’s registration statement. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, in their sole discretion, to limit the number of shares included in any such offering under certain circumstances, but not below 15% of the total amount of securities included in such offering, unless all securities, other than the Company’s securities, are entirely excluded from the offering.

     

      •  

    Form S-3 Registration Rights. At any time after the Company is qualified to file a registration statement on Form S-3, and subject to limitations and conditions, the holders of 50% or more of the registrable securities then outstanding are entitled to written notice of such registration and may make a written request that the Company prepare and file a registration statement on Form S-3 under the Securities Act covering their shares. The Company will then prepare and file the Form S-3 registration statement as requested, unless, in the good faith judgment of the Company’s board of directors, such registration would be seriously detrimental to the Company and its stockholders and filing should be deferred.


    On November 10, 2020, the Company and the other stockholders party thereto entered into Amendment No. 1 to the Investors’ Rights Agreement in order to provide for the registration of the shares of Common Stock issued or issuable upon conversion of the Convertible Promissory Note.

    On December 7, 2020, the Company and the other stockholders party thereto entered into Amendment No. 2 to the Investors’ Rights Agreement in order to provide for the registration of the shares of Common Stock issued or issuable upon conversion of the 7.25% Convertible Notes.

    On May 31, 2021, the Company and the other stockholders party thereto entered into Amendment No. 3 to the Investors’ Rights Agreement in order to provide for the registration of the shares of Common Stock issued pursuant to the Stock Issuance Agreement.

    On August 19, 2021, in connection with the proposed sale by the Company of Common Stock and warrants to purchase Common Stock pursuant to the Company’s registration statement on Form S-3 filed with the SEC on July 30, 2021 (the “Shelf Registration Statement”), the Company and the stockholders party to the Investors’ Rights Agreement entered into that certain Notice and Waiver, pursuant to which such stockholders waived their respective right to request that the Company include the securities registrable pursuant to the Investor Rights Agreement among the securities registered on the Shelf Registration Statement.

    Lock-Up Agreement

    On June 9, 2021, Jeffrey A. Ferrell entered into a lock-up agreement (“Lock-Up Agreement”) with Piper Sandler & Co. (“Piper Sandler”) as private placement agent whereby Mr. Ferrell agreed that, for a period of 90 days following the date of the Lock-Up Agreement subject to certain exceptions, that he will not, directly or indirectly, offer, pledge, announce the intention to sell, contract to sell, sell any option or contract to purchase, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of any of shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or any securities convertible into, or exchangeable for or that represent the right to receive shares of Common Stock (collectively, the “Lock-Up Restrictions”). Piper Sandler may, in its sole discretion, release all or any portion of the shares from the Lock-Up Restrictions.

    Series B Preferred Stock Purchase Warrant

    On October 27, 2017, the Company issued a Series B Preferred Stock Purchase Warrant (as amended, modified, restated, refinanced, replaced or supplemented from time to time, the “Warrant”) to Co-Invest LP as registered holder. Following the initial public offering of the Company, the Warrant is exercisable into 400,160 shares of Common Stock at an exercise price of $13.90 per share, at any time on or prior to its expiration on October 27, 2022.

    7.25% Convertible Notes

    On December 7, 2020, the Company issued a new series of 7.25% Convertible Notes. The 7.25% Convertible Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of December 7, 2020, by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. The initial conversion rate is 278.0094 shares of Common Stock per $1,000 principal amount of 7.25% Convertible Notes, which represents an initial conversion price of approximately $3.60 per share of Common Stock. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.


    Common Stock Warrant

    On June 14, 2021, the Company issued a Common Stock Warrant to Acquisition 2 LP as registered holder. The Common Stock Warrant is exercisable into 8,097,166 shares of Common Stock at an exercise price of $2.84 per share, at any time and from time to time prior to its expiration on June 14, 2026.

    The foregoing summary of the Investors’ Rights Agreement, Lock-up Agreement, Warrant, 7.25% Convertible Notes and Common Stock Warrant is qualified in its entirety by reference to the complete text of such agreements, copies of which are filed as exhibits hereto and are incorporated herein by reference.

    Pursuant to Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Schedule 13D, which agreement is set forth on the signature page to this Schedule 13D.

    Except as described above and herein in this Schedule 13D, there are no other contracts, understandings or relationships (legal or otherwise) among the parties named in Item 2 hereto and between such persons and any person with respect to any of the common stock of the Company owned by the Funds.

     

    Item 7.

    Material to be Filed as Exhibits.

     

    Exhibit 99.1    Fourth Amended and Restated Investors’ Rights Agreement, dated August  27, 2019, by and among the Company and certain of its stockholders (Incorporated by reference to Exhibit 4.5 of the Company’s Registration Statement on Form S-1 filed on May 27, 2020).
    Exhibit 99.2    Amendment No. 1 to Fourth Amended and Restated Investors’ Rights Agreement, dated as of November  10, 2020, by and among the Company and certain of its stockholders (Incorporated by reference to Exhibit 4.6 of the Company’s Registration Statement on Form S-1 filed on December 1, 2020).
    Exhibit 99.3    Amendment No. 2 to Fourth Amended and Restated Investors’ Rights Agreement, dated as of December  7, 2020, by and among the Company and certain of its stockholders (Incorporated by reference to Exhibit 99.3 to the Schedule 13D/A filed by the Reporting Persons on December 11, 2020).
    Exhibit 99.4    Amendment No. 3 to Fourth Amended and Restated Investors’ Rights Agreement, dated as of May  31, 2021, by and among the Company and certain of its stockholders (Incorporated by reference to Exhibit 99.4 to the Schedule 13D/A filed by the Reporting Persons on June 21, 2021).
    Exhibit 99.5    Notice and Waiver, dated as of August 19, 2021, by and among the Company and certain of its stockholders.
    Exhibit 99.6    Series B Preferred Stock Purchase Warrant (Incorporated by reference to Exhibit 4.2 of the Company’s Registration Statement on Form S-1 filed on May 27, 2020).


    Exhibit 99.7    First Amendment to Series B Preferred Stock Purchase Warrant (Incorporated by reference to Exhibit 4.3 of the Company’s Registration Statement on Form S-1 filed on May 27, 2020).
    Exhibit 99.8    Second Amendment to Series B Preferred Stock Purchase Warrant (Incorporated by reference to Exhibit 4.4 of the Company’s Registration Statement on Form S-1 filed on May 27, 2020).
    Exhibit 99.9    Form of Certificate Representing the 7.25% Convertible Notes (Incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed on December 7, 2020).
    Exhibit 99.10    Indenture, dated as of December  7, 2020, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed on December 7, 2020).
    Exhibit 99.11    Form of Warrant (Incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed on June 14, 2021).
    Exhibit 99.12    Form of Lock-Up Agreement, dated as of June  9, 2021, between the Company and the holder thereto (Incorporated by reference to Exhibit C to the Securities Purchase Agreement filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June  14, 2021).


    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13D with respect to the common stock of the Company.

    Dated as of August 27, 2021.

     

    ATHYRIUM OPPORTUNITIES FUND (A) LP
      By:   ATHYRIUM OPPORTUNITIES ASSOCIATES LP, its General Partner
        By:   ATHYRIUM OPPORTUNITIES ASSOCIATES GP LLC, its General Partner
        By:  

    /s/ Christian Neira

        Name:   Christian Neira
        Title:   Authorized Signatory
    ATHYRIUM OPPORTUNITIES FUND (B) LP
      By:   ATHYRIUM OPPORTUNITIES ASSOCIATES LP, its General Partner
        By:   ATHYRIUM OPPORTUNITIES ASSOCIATES GP LLC, its General Partner
        By:  

    /s/ Christian Neira

        Name:   Christian Neira
        Title:   Authorized Signatory


    ATHYRIUM OPPORTUNITIES ASSOCIATES LP
    By:   ATHYRIUM OPPORTUNITIES ASSOCIATES GP LLC, its General Partner
    By:  

    /s/ Christian Neira

    Name:   Christian Neira
    Title:   Authorized Signatory
    ATHYRIUM OPPORTUNITIES ASSOCIATES GP LLC
    By:  

    /s/ Christian Neira

    Name:   Christian Neira
    Title:   Authorized Signatory
    ATHYRIUM CAPITAL MANAGEMENT, LP
    By:  

    /s/ Jeffrey A. Ferrell

    Name:   Jeffrey A. Ferrell
    Title:   President
    ATHYRIUM CAPITAL HOLDINGS, LLC
    By:  

    /s/ Jeffrey A. Ferrell

    Name:   Jeffrey A. Ferrell
    Title:   Managing Member

    /s/ Jeffrey A. Ferrell

    JEFFREY A. FERRELL


    ATHYRIUM OPPORTUNITIES ADVISERS LLC
      By:   NB ALTERNATIVES ADVISERS LLC,
        its Sole Member
      By:  

    /s/ Christian Neira

      Name:   Christian Neira
      Title:   Authorized Signatory
    NB ALTERNATIVES ADVISERS LLC
    By:  

    /s/ Christian Neira

    Name:   Christian Neira
    Title:   Authorized Signatory
    NB ALTERNATIVES GP HOLDINGS LLC
    By:  

    /s/ Christian Neira

    Name:   Christian Neira
    Title:   Authorized Signatory
    NB ALTERNATIVES HOLDINGS LLC
    By:  

    /s/ Christian Neira

    Name:   Christian Neira
    Title:   Authorized Signatory
    ATHYRIUM OPPORTUNITIES 2020 LP
    By:   ATHYRIUM OPPORTUNITIES ASSOCIATES III LP, its General Partner
      By:   ATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLC, its General Partner
      By:  

    /s/ Andrew Hyman

      Name:   Andrew Hyman
      Title:   Senior Vice President, Secretary


    ATHYRIUM OPPORTUNITIES III ACQUISITION LP
    By:   ATHYRIUM OPPORTUNITIES ASSOCIATES III LP, its General Partner
      By:   ATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLC, its General Partner
      By:  

    /s/ Andrew Hyman

      Name:   Andrew Hyman
      Title:   Senior Vice President, Secretary
    ATHYRIUM OPPORTUNITIES III ACQUISITION 2 LP
    By:   ATHYRIUM OPPORTUNITIES ASSOCIATES III LP, its General Partner
      By:   ATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLC, its General Partner
      By:  

    /s/ Andrew Hyman

      Name:   Andrew Hyman
      Title:   Senior Vice President, Secretary
    ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
    By:   ATHYRIUM OPPORTUNITIES ASSOCIATES CO-INVEST LLC, its General Partner
    By:  

    /s/ Andrew Hyman

    Name:   Andrew Hyman
    Title:   Senior Vice President, Secretary


    ATHYRIUM OPPORTUNITIES ASSOCIATES CO-INVEST LLC
    By:  

    /s/ Andrew Hyman

    Name:   Andrew Hyman
    Title:   Senior Vice President, Secretary
    ATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLC
    By:  

    /s/ Andrew Hyman

    Name:   Andrew Hyman
    Title:   Senior Vice President, Secretary
    ATHYRIUM OPPORTUNITIES ASSOCIATES III LP
    By:   ATHYRIUM OPPORTUNITIES ASSOCIATES III GP LLC, its General Partner
    By:  

    /s/ Andrew Hyman

    Name:   Andrew Hyman
    Title:   Senior Vice President, Secretary
    ATHYRIUM FUNDS GP HOLDINGS, LLC
    By:  

    /s/ Jeffrey A. Ferrell

    Name:   Jeffrey A. Ferrell
    Title:   Managing Member


    ANNEX A

    Other than as set forth below, and in the Schedule 13D to which this Annex A is attached, none of the Reporting Persons have appointed any executive officers or directors.

    Athyrium Opportunities Associates GP LLC

    The name and principal occupation of each of the members and executive officers of Athyrium Opportunities Associates GP LLC are listed below:

     

    Name

      

    Principal Occupation

    Athyrium Capital Management, LP    N/A (Member)
    NB Alternatives GP Holdings LLC    N/A (Member)
    Jeffrey A. Ferrell    President
    Samuel Porat    President
    Paul Wakefield    Senior Vice President
    Andrew C. Hyman    Senior Vice President
    Jeremy Lack    Senior Vice President
    Christian Neira    Managing Director and Assistant Secretary
    Kelly Maughan    Senior Vice President and Assistant Secretary
    Kimberly Marlar    Vice President and Assistant Secretary
    Courtney Paul    Vice President

    Athyrium Capital Management, LP

    The name and principal occupation of each of the members and executive officers of Athyrium Capital Management, LP are listed below:

     

    Name

      

    Principal Occupation

    Athyrium Capital Holdings, LLC    N/A (General Partner)
    Jeffrey A. Ferrell    President
    Jeremy D. Lack    President
    Andrew C. Hyman    Senior Vice President, Secretary
    Paul A. Wakefield    Senior Vice President
    Courtney Paul    Vice President, Assistant Secretary
    Rashida Adams    Vice President

    Athyrium Capital Holdings, LLC

    The name and principal occupation of each of the members of Athyrium Capital Holdings, LLC is listed below:

     

    Name

      

    Principal Occupation

    Jeffrey A. Ferrell    Managing Member
    Jeremy D. Lack    Member


    Athyrium Opportunities Advisers LLC

    The name and principal occupation of each of the members and executive officers of Athyrium Opportunities Advisers LLC are listed below:

     

    Name

      

    Principal Occupation

    NB Alternatives Advisers LLC    N/A (Member)
    Anthony Tutrone    Chief Executive Officer and Managing Director
    Samuel Porat    Managing Director
    Christian Neira    Managing Director
    Brien Smith    Managing Director and Chief Operating Officer
    Mark Salzberg    Senior Vice President and Chief Compliance Officer
    Kelly Maughan    Senior Vice President
    Teale Long    Senior Vice President
    Leila Biederman    Senior Vice President
    Kimberly Marlar    Vice President and Assistant Secretary

    NB Alternatives Advisers LLC

    The name and principal occupation of each of the members and executive officers of NB Alternatives Advisers LLC are listed below:

     

    Name

      

    Principal Occupation

    NB Alternatives Holdings LLC    N/A (Member)
    Neuberger Berman AA LLC    N/A (Member)
    Anthony Tutrone    Chief Executive Officer and Managing Director
    John Buser    President and Managing Director
    D. Pike Aloian    Managing Director
    William Arnold    Managing Director
    Baffour Asante-Abedi    Managing Director
    Milca Beltre    Managing Director and Assistant Treasurer
    Matthew Bird    Managing Director
    Peter Bock    Managing Director
    James Bowden    Managing Director
    Manuela Cattaneo    Managing Director
    Kent Chen    Managing Director
    Patrick Deaton    Managing Director
    Paul Daggett    Managing Director
    Peter DiFiore    Managing Director
    Cedric Drui    Managing Director
    Ethan Falkove    Managing Director
    Jose Luis Gonzalez Pastor    Managing Director
    Ian Haas    Managing Director
    Justin Hakimian    Managing Director
    David Haltiner    Managing Director
    Fred Ingham    Managing Director
    Matthew Kaplan    Managing Director
    Susan Kasser    Managing Director
    Maura Reilly Kennedy    Managing Director
    Scott Koenig    Managing Director


    Andrew Komaroff    Managing Director and Chief Administrative Officer
    David Kupperman    Managing Director
    Michael Kramer    Managing Director
    Zhengyuan Lu    Managing Director
    David Lyon    Managing Director
    Jeff Majit    Managing Director
    David Morse    Managing Director
    Christian Neira    Managing Director and Secretary
    Josh Overbay    Managing Director
    Philipp Patschkowski    Managing Director
    Tristram Perkins    Managing Director
    Benjamin Perl    Managing Director
    Samuel Porat    Managing Director
    Will Proctor    Managing Director
    Joanna Rocha Scaff    Managing Director
    Michael Schwartz    Managing Director
    Linda Sharaby    Managing Director and Assistant Secretary
    Jonathan Shofet    Managing Director
    Zachary Sigel    Managing Director
    Andrew Silberstein    Managing Director
    Brien Smith    Managing Director and Chief Operating Officer
    Peter Sterling    Managing Director
    David Stonberg    Managing Director
    Brian Talbot    Managing Director
    Elizabeth Traxler    Managing Director
    Peter Von Lehe    Managing Director
    Jacquelyn Wang    Managing Director
    Matthew Wolpert    Managing Director
    Yoshiyuki Yagisawa    Managing Director
    Patricia Miller Zollar    Managing Director
    Jay Berger    Senior Vice President
    Leila Biederman    Senior Vice President and Assistant Secretary
    Mark Bonner Jr.    Senior Vice President
    Kaci Boyer    Senior Vice President
    Jeffrey Brooks    Senior Vice President
    Michael Chinni    Senior Vice President and Controller
    Kevin Chiu    Senior Vice President
    Alex Conyers    Senior Vice President
    Alexandra Cooke    Senior Vice President
    Tyler Czinege    Senior Vice President
    Krystle DaSilva    Senior Vice President
    Michelle De Piante    Senior Vice President
    Jeannette Donkervoet    Senior Vice President
    Dominique Drenckhahn    Senior Vice President
    Hiroyki Fukuda    Senior Vice President
    Frank Guglielmo    Senior Vice President
    Henry Herms    Senior Vice President
    Boryana Karastoyanova    Senior Vice President


    Avery Kiser    Senior Vice President
    Victor Ko    Senior Vice President
    Nikhil Krishnan    Senior Vice President
    Eric Lai    Senior Vice President
    Steven Lloyd    Senior Vice President
    Teale Long    Senior Vice President and Assistant Secretary
    Farshad Mashayekhi    Senior Vice President
    Doug Manor    Senior Vice President and Principal
    Kelly Maughan    Senior Vice President
    Joshua Miller    Senior Vice President and Principal
    Sandeep Mirani    Senior Vice President
    Michael O’Neill    Senior Vice President
    Jacqueline Reshef    Senior Vice President
    Ted Rykowski    Senior Vice President
    Mark Salzberg    Senior Vice President and Chief Compliance Officer
    Paresh Shah    Senior Vice President
    Rishi Shah    Senior Vice President
    Michael Smith    Senior Vice President
    Niketh Velamoor    Senior Vice President and Senior Anti-Money Laundering Officer
    Sophie Ware    Senior Vice President
    Madeline Wick    Senior Vice President
    Matt Wiener    Senior Vice President and Principal
    Brock Williams    Senior Vice President and Principal
    Dean Winick    Senior Vice President
    David Zolot    Senior Vice President
    Julie Atwell    Vice President
    Faryn Altschuler    Vice President
    Jeremy Deutsch    Vice President
    Colin Foley    Vice President
    Mario Giuliani    Vice President
    David Leimgruber    Vice President
    Yilun Li    Vice President
    Amy Liu    Vice President
    Manuel Lorenzo    Vice President
    Jordan Mark    Vice President
    Kimberly Marlar    Vice President and Assistant Secretary
    Di Meng    Vice President
    Yi Pan    Vice President
    Declan Redfern    Vice President
    Christopher Rosser    Vice President
    Jocelyn Ryan    Vice President and Assistant Secretary
    Ana Roa Sarmiento    Vice President
    Giannina Sy    Vice President
    Matthew Tai    Vice President
    Langston Theis    Vice President
    Kimberly Yuhas    Vice President and Assistant Secretary
    Leo Viola    Senior Vice President and Treasurer


    NB Alternatives GP Holdings LLC

    The name and principal occupation of each of the members and executive officers of NB Alternatives GP Holdings LLC are listed below:

     

    Name

      

    Principal Occupation

    NB Alternatives Holdings LLC    N/A (Member)
    Anthony Tutrone    Director, Chief Executive Officer and Managing Director
    John Buser    President and Managing Director
    Andrew Komaroff    Managing Director and Chief Administrative Officer
    William Arnold    Managing Director
    Manuela Cattaneo    Managing Director
    Matthew Kaplan    Managing Director
    David Morse    Managing Director
    Christian Neira    Managing Director and Assistant Secretary
    Tristram Perkins    Managing Director
    Jonathan Shofet    Managing Director
    Brien Smith    Managing Director and Chief Operating Officer
    David Stonberg    Managing Director
    Mark Salzberg    Senior Vice President and Chief Compliance Officer
    Henry Herms    Senior Vice President
    Michael Beebe    Senior Vice President
    Kimberly Marlar    Vice President and Assistant Secretary
    Leo Viola    Treasurer
    Milca Beltre    Head of Tax

    NB Alternatives Holdings LLC

    The name and principal occupation of each of the members and executive officers of NB Alternatives Holdings LLC are listed below:

     

    Name

      

    Principal Occupation

    Neuberger Berman AA LLC    N/A (Member)
    Neuberger Berman Group LLC    N/A (Member)
    Andrew Komaroff    Director, President and Chief Executive Officer
    William Arnold    Chief Financial Officer and Executive Vice President
    Heather Zuckerman    Executive Vice President
    Leo Anthony Viola    Treasurer
    Milca Beltre    Head of Tax and Managing Director
    Kelly Maughan    Assistant Treasurer
    Linda Sharaby    Secretary
    Elvira DeCaro    Assistant Secretary
    Christian Neira    Managing Director
    Michael Chinni    Controller


    Athyrium Opportunities Co-Invest LLC

    The name and principal occupation of each of the members and executive officers of Athyrium Opportunities Co-Invest LLC are listed below:

     

    Name

      

    Principal Occupation

    Athyrium Funds GP Holdings LLC    N/A (Managing Member)
    Jeffrey A. Ferrell    President
    Jeremy D. Lack    President
    Andrew C. Hyman    Senior Vice President, Secretary
    Paul A. Wakefield    Senior Vice President
    Courtney Paul    Vice President, Assistant Secretary
    Elin Strong    Vice President
    Rashida Adams    Vice President

    Athyrium Opportunities Associates III GP LLC

    The name and principal occupation of each of the members and executive officers of Athyrium Opportunities Associates III GP LLC are listed below:

     

    Name

      

    Principal Occupation

    Athyrium Funds GP Holdings LLC    N/A (Managing Member)
    Jeffrey A. Ferrell    President
    Jeremy D. Lack    President
    Andrew C. Hyman    Senior Vice President, Secretary
    Paul A. Wakefield    Senior Vice President
    Courtney Paul    Vice President, Assistant Secretary
    Elin Strong    Vice President
    Rashida Adams    Vice President
    Get the next $PROG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PROG

    DatePrice TargetRatingAnalyst
    11/4/2021$59.00 → $57.00Overweight → Equal-Weight
    Stephens
    10/14/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PROG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Progenity Announces Successful Transfer of Liquid Biopsy Technologies

      SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics technologies, including single-molecule detection, which are designed to enable next-generation rapid, low-cost assessment of biomolecules via liquid biopsy. Under the terms of the agreement, Progenity is contributing all assets related to the technologies to newly formed Enumera Molecular, Inc., which intends to develop and commercialize them. Progenity will receive an ownership stake in the company. "Enumera Molecular was founded as a life science tools company focused on developing a scalab

      5/5/22 6:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.

      SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update. As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings c

      5/3/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms

      SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations. Mr. Shabram brings over 30 years of biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. "We are delighted to have Paul Shabram on board as we accelerate and expand our development programs," said Adi Mohanty, Chief Executive Officer. "We have generated strong preclinical data and are in the process of filing for and initi

      4/25/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Financials

    Live finance-specific insights

    See more
    • Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.

      SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update. As previously announced, Progenity is changing to Biora Therapeutics. Biora will focus on its pipeline of targeted and systemic oral biotherapeutics. The legal name change was completed on April 26, 2022, and the brand launch for Biora Therapeutics™ will coincide with the earnings c

      5/3/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update

      SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 877-423-9813 for domestic callers or 201-689-8573 for international callers and entering the conference code:

      3/16/22 4:23:00 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update

      SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced that it will report third quarter 2021 financial results on Wednesday, November 10, 2021 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 833-519-1237 for domestic callers or 914-800-3810 for international callers, and entering the conference code: 9763335. A live webcast and archive of the call will be available online from the investor relations section of the compa

      11/3/21 7:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Athyrium Opportunities Iii Co-Invest 1 Lp returned 42,362 units of Series X Preferred Stock to the company

      4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

      1/5/23 4:55:13 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4: Kotzin Brian L. returned 44 units of Series X Preferred Stock to the company, closing all direct ownership in the company

      4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

      1/5/23 4:06:20 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form 4: Mohanty Aditya P. returned 178 units of Series X Preferred Stock to the company, closing all direct ownership in the company

      4 - BIORA THERAPEUTICS, INC. (0001580063) (Issuer)

      1/5/23 4:06:00 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progenity downgraded by Stephens with a new price target

      Stephens downgraded Progenity from Overweight to Equal-Weight and set a new price target of $57.00 from $59.00 previously

      11/4/21 7:18:22 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • HC Wainwright & Co. initiated coverage on Progenity with a new price target

      HC Wainwright & Co. initiated coverage of Progenity with a rating of Buy and set a new price target of $4.00

      10/14/21 6:20:58 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity downgraded by Raymond James

      Raymond James downgraded Progenity from Outperform to Market Perform

      6/3/21 7:08:09 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Leadership Updates

    Live Leadership Updates

    See more
    • Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms

      SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations. Mr. Shabram brings over 30 years of biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. "We are delighted to have Paul Shabram on board as we accelerate and expand our development programs," said Adi Mohanty, Chief Executive Officer. "We have generated strong preclinical data and are in the process of filing for and initi

      4/25/22 9:00:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Appoints Adi Mohanty as Chief Executive Officer

      SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, today announced the appointment of Adi Mohanty as Chief Executive Officer of the company, effective November 8, 2021. Mr. Mohanty also joins the Progenity Board of Directors. "As we complete the execution of our strategic transformation, we are continuing to build biotechnology and biotherapeutics leadership capabilities to help ensure our success," said Eric d'Esparbes, Chief Financial Officer and interim CEO. "To this end, we are delighted to welcome Adi Mohanty to Progenity as Chief Executive Officer. We believe he is the right person to lead Progenity into this next phase o

      11/9/21 6:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Announces Appointment of Surbhi Sarna to its Board of Directors

      SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ:PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi's medical device experience and her focus on development of strategic partnerships will prove valuable as the company advances its innovation pipeline. "As part of our strategic transformation, we are sharpening our focus on efforts to develop the drug discovery and delivery systems of the future. We are delighted that Surbhi Sarna has agreed to join the Progenity Board of Directors to support these efforts," said Harry Stylli, Ph.D., CEO, Chairman of the Board, and co-founder

      6/30/21 7:30:00 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    SEC Filings

    See more
    • Progenity Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

      1/20/23 4:05:58 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

      1/12/23 6:06:03 AM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • Progenity Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - BIORA THERAPEUTICS, INC. (0001580063) (Filer)

      1/9/23 4:02:56 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables

    $PROG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Progenity Inc. (Amendment)

      SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)

      1/12/23 4:46:00 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13D/A filed by Progenity Inc. (Amendment)

      SC 13D/A - BIORA THERAPEUTICS, INC. (0001580063) (Subject)

      11/18/22 4:30:56 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables
    • SEC Form SC 13G/A filed by Progenity Inc. (Amendment)

      SC 13G/A - PROGENITY, INC. (0001580063) (Subject)

      2/14/22 3:32:06 PM ET
      $PROG
      Specialty Chemicals
      Consumer Durables